Nektar Therapeutics (NKTR) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $85.33: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 3.29; Below-average business quality.
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on immunotherapy, with a pipeline including rezpegaldesleukin (autoimmune), NKTR-255 (oncology), and NKTR-0165. The company has no commercial product revenue and is funded primarily through equity sales... Read more
Sell if holding. Engine safety override at $85.33: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 3.29; Below-average business quality. Chart setup: RSI 59 mid-range, Bollinger mid-band. Score 4.3/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductrezpegaldesleukin10-K Item 1A: 'We are highly dependent on the success of drug candidates, particularly rezpegaldesleukin (previously referred to as NKTR-358).'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
5 floor-breakers·1 ceiling hit
Revenue shrinking — -25.3% YoY. Growth thesis broken unless recovery story develops.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Volatile — 7.5% daily ATR makes tight stops impractical. Position-size conservatively.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -297.1%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $85.33: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 3.29; Below-average business quality. Chart setup: RSI 59 mid-range, Bollinger mid-band. Prior stop was $79.36. Score 4.3/10, moderate confidence.
Take-profit target: $125.50 (+47.1% upside). Prior stop was $79.36. Stop-loss: $79.36.
Concentration risk — Product: rezpegaldesleukin; Quality below floor (3.7 < 4.0); Value-trap signals (2/5): Margin compression (op margin -3.4%), Material insider selling (104 sells, 0.27% of cap).
Nektar Therapeutics trades at a P/E of N/A (forward -7.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
16 analysts cover NKTR with a consensus score of 4.3/5. Average price target: $144.
What does Nektar Therapeutics do?Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on immunotherapy, with a pipeline including...
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on immunotherapy, with a pipeline including rezpegaldesleukin (autoimmune), NKTR-255 (oncology), and NKTR-0165. The company has no commercial product revenue and is funded primarily through equity sales and collaboration agreements.